Patent ID: 11918574
Assignee: BEYONDSPRING PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 7:
8. A method of therapeutically treating a cancer characterized by expressing a mutant form of a RAS protein, comprising administering Plinabulin to a subject in need thereof,
wherein the mutant form of the RAS protein is a mutant form of a NRAS protein that comprises one or more amino acid substitutions selected from the group consisting of Q61R, Q61L, and Q61H, or is a mutant form of a KRAS protein that comprises one or more amino acid substitutions selected from the group consisting of G12A, G12C, G12D, G12V, G13D, and G13C, and
wherein the cancer is selected from multiple myeloma, endometrial cancer, colorectal cancer, renal cancer, and pancreatic cancer.